This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

BeneFIX (nonacog alfa) Prescribing Information for Great Britain click here. BeneFIX (nonacog alfa) Prescribing Information for Northern Ireland click here.
​​​​​​​
Adverse event reporting can be found at the bottom of this page.    

​​​​​​​BeneFIX® (nonacog alfa) is recombinant coagulation factor IX indicated for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). BeneFIX® can be used for all age groups.1  

Recommended dosing schedules1

BeneFIX® offers frequent, flexible dosing so your patients are covered for everyday life.1,2  

No two days are the same. No two patients are the same. BeneFIX® offers frequent, flexible dosing so your patients are covered for everyday life.1,2

​​​​​​​BeneFIX® can be administered as on-demand or prophylactic treatment.1  

Prophylaxis

​​​​​​​In the case of the following haemorrhagic events, the factor IX activity should not fall below the given plasma activity levels (in percentage of normal or in IU/dl) in the corresponding period.1    
The following table can be used to guide dosing in bleeding episodes and surgery:  

Degree of haemorrhage/Type of surgical procedure

Factor IX​​​​​​​ level required (%) or (IU/dL)

Frequency of doses (hours) / Duration of therapy (days)

​​​​​​​Haemorrhage

 

 

​​​​​​​Early haemarthrosis, muscle bleeding or oral bleeding

20–40

Repeat every 24 hours. At least 1 day, until the bleeding episode as indicated by pain is resolved or healing is achieved.

More extensive haemarthrosis, muscle bleeding or haematoma 

30–60

Repeat infusion every 24 hours for 3–4 days or more until pain and acute disability are resolved.

Life-threatening haemorrhage

60–100

Repeat infusion every 8–24 hours until threat is resolved.

Surgery

 

 

Minor surgery including tooth extraction

30–60

Every 24 hours, at least 1 day, until healing is achieved.

Major surgery

80–100 (pre- and post- operative)

Repeat infusion every 8-24 hours until adequate wound healing, then therapy for at least another 7 days to maintain a factor IX activity of 30% to 60% (IU/dL)

Adapted from BeneFIX® (nonacog alfa) Summary of Product Characteristics.1  

On-demand treatment

Needleless reconstitution  

Pre-filled syringe in transparent vial adapter.1  ​​​​​​​

Pre filled diluents range means fewer components and faster preparation Needleless rapid reconstitution to avoid accidental punctures

Clear vial adapter to easily confirm a good connexion

Dosing flexibility  
Wide range of dosages available so you can individualise factor IX coverage for your patients.

Colour-coded for easy identification of doses low 5 ml reconstitution volume for all vial sizes  

Rate of administration should be determined by the patient's level of comfort (but no more than 4ml/minute) ​​​​​​​

Patients may vary in their response to factor IX, demonstrating different half-lives and recoveries.1    

​​​​​​​Shorter dose intervals or higher doses may be necessary to deliver adequate coverage based on patient’s bleeding phenotype, levels of physical activity, and preference regarding convenience and adherence.1–2  ​​​​​​
​​​​​​​

Dose optimisation with BeneFIX®   

Explore more

Administration and storage

The R2 device is used for reconstitution of BeneFIX® by injection.

Find out more

Monitoring

Learn about monitoring BeneFIX® in your patients.  

Find out more

Pfizer support for patients

Pfizer Ltd. is committed to helping patients manage their day-to-day lives.  

Find out more

** This is an optional area where footnotes can live.

Heritage

BeneFIX® has more than 20 years’ experience in haemophilia B, building on a proud heritage in haemophilia care.1

Find out more

** This is an optional area where footnotes can live.

Contact us

Contact a member of the Pfizer haemophilia team.

Contact us

** This is an optional area where footnotes can live.


References
  1. BeneFIX® Summary of Product Characteristics. For Great Britain, available here. For Northern Ireland, available here.
  2. Shapiro AD et al. Haemophilia 2005;11:571–582.  
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
​​​​​​​Adverse events should also be reported to Pfizer Medical Information on 01304 616161.

PP-BEN-GBR-0489. September 2021.

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No